Biodexa Pharmaceuticals PLC Exercise of Pre-Funded Warrants & Issue of Equity (9747W)

TIDMBDRX

RNS Number : 9747W

Biodexa Pharmaceuticals PLC

20 April 2023

20 April 2023

Biodexa Pharmaceuticals PLC

("Biodexa" or the "Company")

Exercise of Pre-Funded Warrants and Issue of Equity

Total Voting Rights

Biodexa Pharmaceuticals PLC (AIM: BDRX; Nasdaq: BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has yesterday issued to an investor 6,275,465 new ordinary shares of GBP0.02 each in the Company ("New Ordinary Shares"), pursuant to exercise notices in respect of 1,255,093 Pre-Funded Warrants received on 18 April 2023. These Pre-Funded Warrants were exercised at US$0.0004 per Pre-Funded Warrant for gross proceeds of US$502.04. Further details are set out in the Company's circular dated 7 March 2023.

Admission and total voting rights

Application has been made to the London Stock Exchange plc for the admission to trading on AIM of the New Ordinary Shares, which is expected to become effective and dealings commence at 8.00 a.m. on or around 25 April 2023 ("Admission"). The New Ordinary Shares will rank pari passu with the existing ordinary shares.

The Company's enlarged issued share capital on Admission will comprise 94,629,412 ordinary shares, each with voting rights. The Company does not hold any shares in treasury. From Admission, expected to take place on 25 April 2023, this figure of 94,629,412 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined, capitalised terms used in this announcement have the same meanings as ascribed to them in the Company's circular dated 7 March 2023.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014, as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended.

For more information, please contact :

 
 Biodexa Pharmaceuticals PLC 
 Stephen Stamp, CEO, CFO 
 Tel: [phone] 
 www.biodexapharma.com 
 
 Strand Hanson Limited (Nominated Adviser and Broker) 
 James Dance / Matthew Chandler / Rob Patrick 
 Tel: [phone] 
 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: [phone] 
 Email: [e-mail] 
 
 Edison Group (US Investor Relations) 
  Alyssa Factor 
  Tel: [phone] 
  Email: [e-mail] 
            About Biodexa Pharmaceuticals PLC 
              Biodexa Pharmaceuticals PLC (dual listed on AIM: BDRX; and NASDAQ: 
              BDRX) is a drug delivery technology company focused on improving 
              the bio-delivery and bio-distribution of medicines . The Company 
              combines approved and development medications with its proprietary 
              and innovative drug delivery technologies to provide compelling 
              products that have the potential to powerfully impact the lives 
              of patients. 
 
              The Company has developed three in-house technology platforms, 
              each with its own unique mechanism to improve delivery of medications 
              to sites of disease. All of the Company's technologies have successfully 
              entered human use in the clinic, providing important validation 
              of the potential for each platform: 
 
               *    Q-Sphera(TM) platform: a disruptive micro-technology 
                    used for sustained release to prolong and control the 
                    release of therapeutics over an extended period of 
                    time (from weeks to months). 
 
 
               *    MidaSolve(TM) platform: an innovative nanotechnology 
                    used to dissolve insoluble drugs so that they can be 
                    administered in liquid form directly and locally into 
                    tumours. 
 
 
               *    MidaCore(TM) platform: a leading-edge nanotechnology 
                    used for targeting medications to sites of disease. 
 
 
 
              The platform nature of the technologies offers the potential to 
              develop multiple drug assets rather than being reliant on a limited 
              number of programmes. Biodexa's technologies are supported by 36 
              patent families including 120 granted patents and an additional 
              70 patent applications. Biodexa's headquarters and R&D facility 
              is in Cardiff, UK. 
 
              Forward-Looking Statements 
 
              Certain statements in this announcement may constitute "forward-looking 
              statements" within the meaning of legislation in the United Kingdom 
              and/or United States. Any forward-looking statements are based 
              on currently available competitive, financial and economic data 
              together with management's views and assumptions regarding future 
              events and business performance as of the time the statements are 
              made and are subject to risks and uncertainties. The Company wishes 
              to caution you that there are some known and unknown factors that 
              could cause actual results to differ materially from any future 
              results, performance or achievements expressed or implied by such 
              forward-looking statements. 
 
              Reference should be made to those documents that the Company shall 
              file from time to time or announcements that may be made by the 
              Company in accordance with the London Stock Exchange's AIM Rules 
              for Companies ("AIM Rules"), the Disclosure and Transparency Rules 
              ("DTRs") and the rules and regulations promulgated by the US Securities 
              and Exchange Commission, which contains and identifies other important 
              factors that could cause actual results to differ materially from 
              those contained in any projections or forward-looking statements. 
              These forward-looking statements speak only as of the date of this 
              announcement. All subsequent written and oral forward-looking statements 
              by or concerning the Company are expressly qualified in their entirety 
              by the cautionary statements above. Except as may be required under 
              the AIM Rules or the DTRs or by relevant law in the United Kingdom 
              or the United States, the Company does not undertake any obligation 
              to publicly update or revise any forward-looking statements because 
              of new information, future events or otherwise arising. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRSELFMSEDSELL

(END) Dow Jones Newswires

April 20, 2023 12:46 ET (16:46 GMT)